Debio1453 is a first-in-class antibiotic candidate that targets an enzyme that’s essential for the growth of Neisseria gonorrhoeae.
Adults who were physically active before COVID infection still had impairments years later.
Among confirmed cases, 800 case-patients are unvaccinated against measles.